PTEN and neoplasm: SMYD2 methylates PTEN at Lysine 313 in vitro and in vivo to negatively regulate PTEN tumor suppressor activity, resulting in activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway.